661 related articles for article (PubMed ID: 9622079)
1. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations.
Egorin MJ; Rosen DM; Wolff JH; Callery PS; Musser SM; Eiseman JL
Cancer Res; 1998 Jun; 58(11):2385-96. PubMed ID: 9622079
[TBL] [Abstract][Full Text] [Related]
2. Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats.
Musser SM; Egorin MJ; Zuhowski EG; Hamburger DR; Parise RA; Covey JM; White KD; Eiseman JL
Cancer Chemother Pharmacol; 2003 Aug; 52(2):139-46. PubMed ID: 12761648
[TBL] [Abstract][Full Text] [Related]
3. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
[TBL] [Abstract][Full Text] [Related]
4. Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice.
Xu L; Eiseman JL; Egorin MJ; D'Argenio DZ
J Pharmacokinet Pharmacodyn; 2003 Jun; 30(3):185-219. PubMed ID: 14571691
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.
Egorin MJ; Lagattuta TF; Hamburger DR; Covey JM; White KD; Musser SM; Eiseman JL
Cancer Chemother Pharmacol; 2002 Jan; 49(1):7-19. PubMed ID: 11855755
[TBL] [Abstract][Full Text] [Related]
6. Biotransformation of geldanamycin and 17-allylamino-17-demethoxygeldanamycin by human liver microsomes: reductive versus oxidative metabolism and implications.
Lang W; Caldwell GW; Li J; Leo GC; Jones WJ; Masucci JA
Drug Metab Dispos; 2007 Jan; 35(1):21-9. PubMed ID: 17012542
[TBL] [Abstract][Full Text] [Related]
7. In vitro metabolism by mouse and human liver preparations of halomon, an antitumor halogenated monoterpene.
Egorin MJ; Rosen DM; Benjamin SE; Callery PS; Sentz DL; Eiseman JL
Cancer Chemother Pharmacol; 1997; 41(1):9-14. PubMed ID: 9443608
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.
Chen X; Bies RR; Ramanathan RK; Zuhowski EG; Trump DL; Egorin MJ
Cancer Chemother Pharmacol; 2005 Mar; 55(3):237-43. PubMed ID: 15503027
[TBL] [Abstract][Full Text] [Related]
9. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action.
Guo W; Reigan P; Siegel D; Ross D
Drug Metab Dispos; 2008 Oct; 36(10):2050-7. PubMed ID: 18635747
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma.
Johnston JS; Phelps MA; Blum KA; Blum W; Grever MR; Farley KL; Dalton JT
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Aug; 871(1):15-21. PubMed ID: 18635408
[TBL] [Abstract][Full Text] [Related]
11. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
Ramanathan RK; Trump DL; Eiseman JL; Belani CP; Agarwala SS; Zuhowski EG; Lan J; Potter DM; Ivy SP; Ramalingam S; Brufsky AM; Wong MK; Tutchko S; Egorin MJ
Clin Cancer Res; 2005 May; 11(9):3385-91. PubMed ID: 15867239
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice.
Smith NF; Hayes A; Nutley BP; Raynaud FI; Workman P
Cancer Chemother Pharmacol; 2004 Dec; 54(6):475-86. PubMed ID: 15526201
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
Chung YL; Troy H; Banerji U; Jackson LE; Walton MI; Stubbs M; Griffiths JR; Judson IR; Leach MO; Workman P; Ronen SM
J Natl Cancer Inst; 2003 Nov; 95(21):1624-33. PubMed ID: 14600095
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole.
Trapnell CB; Jamis-Dow C; Klecker RW; Collins JM
Antimicrob Agents Chemother; 1997 May; 41(5):924-6. PubMed ID: 9145845
[TBL] [Abstract][Full Text] [Related]
15. The biotransformation of isoprene and the two isoprene monoepoxides by human cytochrome P450 enzymes, compared to mouse and rat liver microsomes.
Bogaards JJ; Venekamp JC; van Bladeren PJ
Chem Biol Interact; 1996 Dec; 102(3):169-82. PubMed ID: 9021169
[TBL] [Abstract][Full Text] [Related]
16. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
Kelland LR; Sharp SY; Rogers PM; Myers TG; Workman P
J Natl Cancer Inst; 1999 Nov; 91(22):1940-9. PubMed ID: 10564678
[TBL] [Abstract][Full Text] [Related]
17. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.
Eagling VA; Wiltshire H; Whitcombe IW; Back DJ
Xenobiotica; 2002 Jan; 32(1):1-17. PubMed ID: 11824416
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4.
Feierman DE; Lasker JM
Drug Metab Dispos; 1996 Sep; 24(9):932-9. PubMed ID: 8886601
[TBL] [Abstract][Full Text] [Related]
19. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
Schulte TW; Neckers LM
Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
[TBL] [Abstract][Full Text] [Related]
20. In vitro metabolism of the mammalian soluble epoxide hydrolase inhibitor, 1-cyclohexyl-3-dodecyl-urea.
Watanabe T; Morisseau C; Newman JW; Hammock BD
Drug Metab Dispos; 2003 Jul; 31(7):846-53. PubMed ID: 12814960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]